Kevin Blattner

Kevin Blattner

Currently a PhD student working in the labs of Dr. Daniel Canney and Dr. Benjamin E. Blass. He is currently involved in two projects focusing on the therapeutic utility of a novel piperazinyl-buyrolactones. Compounds in this class show promise as potential therapeutics for IBD (via the 5-HT7 receptor) and Alzheimer’s disease (via the sigma-2 receptor). The bulk of his work involves the synthesis of next generation compounds to develop key SAR that can be used to optimize potency, selectivity and physiochemical properties. The ultimate goal is to develop clinical candidates for treatment of their respective disease states. (dual BS degrees, chem and biochem, Widener Univ.)